IDEAYA Biosciences, Inc. 8-K

What Happened

• On June 3, 2026 IDEAYA Biosciences announced a clinical collaboration with F. Hoffmann‑La Roche Ltd to evaluate IDE892 (IDEAYA’s investigational PRMT5 inhibitor) in combination with Roche’s RG6505 (a pan‑RAS inhibitor) for patients with MTAP‑deleted pancreatic ductal adenocarcinoma (PDAC).
• IDEAYA will sponsor the combination trial and Roche will supply RG6505. IDE892 is currently in a Phase 1 dose‑escalation trial in MTAP‑deleted solid tumors; IDEAYA plans Phase 1 combination cohorts in PDAC with RG6505 and in NSCLC/other tumors with IDE397 (its MAT2A inhibitor). The collaboration may also evaluate a triplet of IDE892 + RG6505 + IDE397 if both parties agree.

Key Details

• Date announced: June 3, 2026 (reported in Form 8‑K, Item 8.01).
• Scientific rationale: MTAP deletion occurs in up to ~40% of PDAC, and almost all MTAP‑deleted PDAC harbor co‑occurring RAS mutations; IDE892 showed robust regressions in MTAP‑deleted preclinical models.
• Rights and governance: Each company retains all commercial rights to its own compound (monotherapy and combinations); a joint governance process will oversee the study; Roche will provide RG6505 supply.
• Development stages: IDE892 — Phase 1 dose escalation; IDE397 — Phase 2 MAT2A inhibitor (company plans combination evaluations).

Why It Matters

• For investors, the collaboration targets a large unmet need: a substantial subset of PDAC patients (~up to 40%) with MTAP deletions and RAS mutations currently lack targeted therapies. A successful combination could materially advance IDEAYA’s MTAP‑deletion strategy.
• This is an early‑stage, co‑development clinical effort—IDEAYA remains the trial sponsor and retains commercial rights for IDE892, but outcomes are uncertain and depend on clinical results, enrollment, and supply/collaboration execution. The filing also includes standard forward‑looking statements and references IDEAYA’s 2026 10‑K and 10‑Q for risk factors.